

Synthesis, Characterization and Antioxidant Activity of Morpholine Mannich Base Derivatives

Amin Henna^{1*}, Wakode Sharad², Tonk Rajiv Kumar¹, Kaur Avneet²

¹Centre for Medicinal Chemistry, Delhi Pharmaceutical Sciences and Research University, Sector-3, Pushp Vihar, New Delhi, India

²Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research, Sector-3, Pushp Vihar, New Delhi, India

Available Online: 25th October, 2017

ABSTRACT

A series of morpholine mannich base derivatives were synthesized by a single step reaction of morpholine with substituted benzaldehydes and N-phenylacetamide. Progress of reaction was monitored by TLC using ethylacetate and n-hexane as mobile phase. The compounds were characterized by ATR and ¹HNMR spectral analysis. Antioxidant assay of the synthesized compounds was done by DPPH and ABTS assay method using Ascorbic acid as standard. The synthesized morpholine mannich base derivatives demonstrated significant radical scavenging property.

Keywords: Morpholine, mannich base, antioxidant

INTRODUCTION

Free radicals which are the products of normal cellular metabolism play an important role in the survival and death of a cell. These are reactive chemical species with a single unpaired electron in the outer orbit and are capable of independent existence. The unstable configuration of free radicals results in abstracting of electron from adjacent substances which in turn become free radicals and ultimately result in damage to the cell¹. Two types of free radicals are ROS (Reactive oxygen species) and RNS (Reactive nitrogen species)². ROS and RNS at optimum concentration are involved in various physiological functions such as cellular signaling pathways, redox regulation, immune function, in mitogenic response^{3,4}. Under normal circumstances they are scavenged by antioxidants which act as defense mechanism. Insufficient levels of antioxidants lead to oxidative stress and nitrosative stress due to increase in production of free radicals. Oxidative stress which is defined as an imbalance between reactive oxygen species and defensive antioxidant system, deregulates number of cellular functions⁵. It is responsible for various pathological states such as ageing⁶, atherosclerosis⁷, aids⁸, cancer⁹, asthma¹⁰, autoimmune diseases such as rheumatic disease¹¹, cardiovascular dysfunction¹², cataract¹³, diabetes^{14,15}, neurodegenerative disease such as Alzheimer's¹⁶ and Parkinson disease¹⁷.

Antioxidants

Antioxidants are substances required at low concentrations for delaying or inhibiting oxidation of a substrate. Thereby, act as scavengers of free radicals¹⁸. Monohydroxy/polyhydroxyphenol groups present in the

structure of antioxidants slow down the pace of lipid peroxidation¹⁹.

Classification of antioxidants

The antioxidants are classified in the following ways:

Gutteridge and Halliwell divided antioxidants into three categories

Primary antioxidants: These are the agents which prevent the formation of oxidants.

Secondary antioxidants: Act as scavengers of ROS.

Tertiary antioxidants: They utilize dietary source or other antioxidants to repair the already oxidized molecules²⁰.

Antioxidants according to their nature and action

Enzymatic antioxidants: Glutathione peroxidase, catalase, superoxide dismutase.

Non-enzymatic antioxidants:

Nutrient antioxidants: Carotenoids, tocopherol, ascorbic acid.

Metabolic antioxidants: Glutathione, thioredoxin, lipoic acid¹⁸.

On the basis of origin

Endogenous antioxidants: Further classified into primary antioxidants which form inactive ROS intermediates (Glutathione, superoxide dismutase, catalase and secondary antioxidants (glutathione reductase, glucose 6 phosphate dehydrogenase) which directly detoxify ROS without formation of any intermediate^{21,22}.

Exogenous/dietary antioxidants: These are obtained from food and various other dietary sources such as vegetables, herbs, spices and vitamins.

Mode of action of antioxidants

Primary or chain breaking antioxidants: Prevent the propagation of the reaction due to formation of less reactive radicals (superoxide dismutase, Vit E).

Reaction Scheme





Table 1: List of synthesized compounds.


| Name | Structure | IUPAC Name |
|------|-----------|---|
| MB-1 | | 3-(morpholino-4-yl)-N-phenyl-3-[2-(trifluoromethyl)phenyl]propanamide |
| MB-2 | | 3-(3-ethoxy-4-hydroxyphenyl)-3-(morpholino-4-yl)-N-phenylpropanamide |
| MB-3 | | 3-(4-(methylthio)phenyl)-3-morpholino-N-phenylpropanamide |
| MB-4 | | 3-(4-bromophenyl)-3-(morpholino-4-yl)-N-phenylpropanamide |

MB-5




3-(morpholin-4-yl)-N-phenyl-3-[4-(trifluoromethyl)phenyl] propanamide

MB-6




3-(morpholin-4-yl)-N-phenyl-3-[4-(piperidin-1-yl)phenyl]propanamide

MB-7




3-[4-(benzyloxy)phenyl]-3-(morpholin-4-yl)-N-phenylpropanamide

MB-8



3-(morpholin-4-yl)-N-phenyl-3-[4-(trifluoromethoxy)phenyl]propanamide

MB-9



3-4-[(4-bromophenyl)methoxy]phenyl-3-(morpholin-4-yl)-N-phenylpropanamide

MB-10

3-(morpholin-4-yl)-N-phenyl-3-[4-(pyrrolidin-1-yl)phenyl]propanamide




Table 2: Physical properties of synthesized compounds.

| Name | Molecular formula | Molecular weight | Percentage Yield | Melting Point ° C | Solubility |
|-------|--|------------------|------------------|-------------------|-------------------------------------|
| MB-1 | C ₂₀ H ₂₁ F ₃ N ₂ O ₂ | 378.39 | 74.3% | 180-184 | Chloroform, DMSO, Ethanol |
| MB-2 | C ₂₁ H ₂₆ N ₂ O ₄ | 370.44 | 36.8% | 293-296 | Chloroform, DMSO, Ethanol, Methanol |
| MB-3 | C ₂₀ H ₂₄ N ₂ O ₂ S | 356.16 | 51.2% | 160-168 | Chloroform, DMSO, Ethanol, Methanol |
| MB-4 | C ₁₉ H ₂₁ BrN ₂ O ₂ | 389.29 | 79.3% | 143-148 | Chloroform, DMSO, Ethanol, Methanol |
| MB-5 | C ₂₀ H ₂₁ F ₃ N ₂ O ₂ | 378.39 | 82.1% | 210-216 | Chloroform, DMSO, Ethanol, Methanol |
| MB-6 | C ₂₄ H ₃₁ N ₃ O ₂ | 393.52 | 29.4% | 239-244 | Chloroform, DMSO, Ethanol |
| MB-7 | C ₂₆ H ₂₈ N ₂ O ₃ | 416.51 | 60.2% | 325-328 | Chloroform, DMSO, Ethanol, Methanol |
| MB-8 | C ₂₀ H ₂₁ F ₃ N ₂ O ₃ | 394.39 | 69.7% | 274-279 | Chloroform, DMSO, Ethanol |
| MB-9 | C ₂₆ H ₂₇ BrN ₂ O ₃ | 495.41 | 28.3% | 306-309 | Chloroform, DMSO, Ethanol, Methanol |
| MB-10 | C ₂₃ H ₂₉ N ₃ O ₂ | 379.50 | 45.8% | 210-211 | Chloroform, DMSO, Ethanol |

Secondary or preventive antioxidants: Block early production of free radicals (catalase, peroxidase)¹⁸.

MATERIALS AND METHODS

All chemicals and solvents for the synthesis were supplied by Sigma Aldrich, Loba Chemie and CDH under certificate of purity. TLC of the newly synthesized compounds was done on Silica gel 60 F-254 coated glass plates purchased from Merck. Scientech-2211 digital auto melting/boiling point apparatus was used for the determination of melting point. Proton magnetic resonance (¹H-NMR) spectra were recorded on Bruker 400 MHz NMR spectrometer using CDCl₃ as solvent. Chemical shifts were reported in parts per million relative to tetramethylsilane (TMS) as an internal standard. IR spectra of the compounds were recorded on Bruker- Alpha 1005151/06 ATIR spectrophotometer.

Synthetic Procedure

An equimolar quantity of morpholine and benzaldehyde were dissolved into ethanol and kept aside for about 10 minutes. To, this solution equimolar concentration of N-phenylacetamide was added. The reaction mixture was refluxed for a period of 5-6 hours at a temperature of 70-75 °C. The progress of the reaction was monitored by TLC, using n-Hexane:Ethyl acetate in the ratio of 2:3 as the mobile phase. The reaction mixture was cooled to room temperature and then poured into ice cold water. The precipitate so obtained was collected by filtration except (MB-3, MB-5, MB-8) which separated as precipitates in the reaction mixture. The precipitates were recrystallized with ethanol.

Antioxidant Assay

The antioxidant assay of the compounds was performed using DPPH and ABTS Assay method.

DPPH Assay

The antioxidant assay was performed by the method of Mensor et al²³. 0.01mM solution of DPPH in methanol was prepared. Methanolic solutions of all the compounds in the following concentration ranges were prepared 40µg/mL, 60µg/mL, 80µg/mL and 100µg/mL. Similarly solutions of ascorbic acid in the same concentration range were prepared. 1mL DPPH solution was added to 1mL sample solution and to ascorbic acid solution as well. Finally volume was made upto 3mL using methanol. The test tubes containing the assay mixture were incubated at a dark and cool place for period of 30 minutes. After incubation the absorbance of the DPPH solution, blank (methanol), samples and ascorbic acid containing DPPH reagent were recorded at 517 nm on a UV-VIS spectrophotometer.

The anti-oxidant activity was measured using the formula % scavenging or inhibition = [(A₀-A_s)/A₀]*100

Where,

A₀= Absorbance of the DPPH solution without sample

A_s= Absorbance of DPPH solution with sample

ABTS assay

7 mM of ABTS stock solution was prepared in water. 2.45mM solution of potassium persulfate was added to it in 1:1 ratio (volume/volume). The reaction mixture was left in a dark place for generation of free radicals for period of about 16 hours. This solution was further diluted using methanol so that it has a stable absorbance of 0.700±0.05 at 734nm. Methanolic solutions of all compounds including ascorbic acid were prepared in the concentration ranges of 40µg/mL, 60µg/mL, 80µg/mL and 100µg/mL. To 0.1ml of the test solutions 1mL of diluted ABTS solutions was added. Absorbance of the test and the standard solutions were taken immediately at 734 nm²⁴.

Table 3: Spectral data of synthesized compounds.

| Name | IR spectra data | ¹ HNMR spectra data (CDCl ₃) |
|-------|---|---|
| MB-1 | 3064 v (CH str in phenyl ring), 1660 v (NHCO), 1315 v (C-N), 1262 v (C-O), 1044 v (C-F) | δ7.50-7.48(5H,Ar-H), 7.33-7.28(3H,Ar-H), 7.12-7.07(1H,NH), 6.65(1H,Ar-H), 4.31(1H,methine),3.70-3.67(4H,O-CH ₂ -morpholine),2.37-2.34(4H,N-CH ₂ -morpholine, 2.16-2.12(2H,CH ₂) |
| MB-2 | 3367 v (OH), 3082 v (CH str in phenyl ring), 1601 v (NHCO), 1317 v (C-N), 1276 v (C-O),1039 v (C-O-C) | δ7.51-7.41(3H,Ar-H),7.33-7.25(2H,Ar-H),7.12-7.07(1H,NH),6.43(3H,Ar-H),5.33(1H,OH),4.60-4.56(2H,methylene),4.32(1H,methine),3.61-3.71(4H,O-CH ₂ -morpholine),2.64(2H,CH ₂),2.17-2.16(4H,N-CH ₂ -morpholine),1.51-1.41(3H,CH ₃) |
| MB-3 | 3064 v (CH str in phenyl ring), 1622 v (NHCO), 1305 v (C-N), 1263 v (C-O), 661 v (S-C) | δ7.69(4H,Ar-H),7.67(1H,NH),7.25-7.00(5H,Ar-H), 4.16(1H,methine),3.73-3.69(4H,O-CH ₂ -morpholine),2.80(3H,CH ₃),2.68(2H,CH ₂), 2.48-2.40(4H,N-CH ₂ -morpholine) |
| MB-4 | 3069 v (CH str in phenyl ring), 1622 v (NHCO), 1320 v (C-N), 1216 v (C-O), 663 v (C-Br) | δ7.78-7.55(5H,Ar-H), 7.33(1H,NH),7.12-7.02(4H,Ar-H), 4.62(1H,methine), δ3.57-3.39(4H,O-CH ₂ -morpholine),2.63-2.58(2H,CH ₂),2.44-2.19(4H,N-CH ₂ -morpholine) |
| MB-5 | 3017 v (CH str in phenyl ring), 1661 v (NHCO), 1327 v (C-N), 1264 v (C-O), 1069 v (C-F) | δ7.63-7.60(4H,Ar-H), 7.50-7.47(1H,NH),7.33-7.26(3H,Ar-H), δ7.23-7.08(2H,Ar-H),4.71-4.47 (1H,methine),3.71-3.66(4H,O-CH ₂ -morpholine),2.89-2.86(2H,CH ₂), δ2.44-2.41(2H,N-CH ₂ -morpholine), 2.31-2.17(2H,N-CH ₂ -morpholine) |
| MB-6 | 3045 v (CH str in phenyl ring), 1669 v (NHCO), 1316 v (C-N), 1227 v (C-O), 1441 v (C-N) | δ7.73-7.70(2H,Ar-H),7.51-7.48(5H,Ar-H),7.34(1H,NH), 6.90-6.87(2H,Ar-H),4.34(1H,methine), 3.41-3.39(4H,O-CH ₂ -morpholine), 3.66(4H,piperidine), 2.34(2H,CH ₂), 2.17(4H,N-CH ₂ -morpholine), 1.67-1.58(6H,piperidine) |
| MB-7 | 3050 v (CH str in phenyl ring), 1680 v (NHCO), 1317 v (C-N), 1255 v (C-O) | δ7.85-7.82(1H,NH), 7.64-7.60(2H,Ar-H),7.42-7.40(5H,Ar-H), 7.26-7.24 (5H,Ar-H),6.38(2H,Ar-H),5.51(2H,O-CH ₂), 4.15(1H,methine), 3.51(4H,O-CH ₂ -morpholine), 2.72(2H,CH ₂), 2.22-2.15(4H,N-CH ₂ -morpholine) |
| MB-8 | 3006 v (CH str in phenyl ring), 1669 v (NHCO), 1314 v (C-N), 1254 v (C-O) | δ7.50(1H,NH), 7.33-7.07(7H,Ar-H), 6.22(2H,Ar-H), 4.50(1H,methine), 3.66-3.59(4H,O-CH ₂ -morpholine),2.69-2.66(2H,CH ₂), 2.43-2.36(4H,N-CH ₂ -morpholine) |
| MB-9 | 3010 v (CH str in phenyl ring), 1650 v (NHCO), 1340 v (C-N), 1201 v (C-O) | δ7.41(1H,NH), 7.38-7.31(4H,Ar-H), 7.25-7.18(4H,Ar-H), 6.90-7.03(5H,Ar-H),5.68(2H,O-CH ₂), 4.43(1H,methine) 3.31-3.29(4H,O-CH ₂ -morpholine),2.41(2H,CH ₂), 2.33-2.29(4H,N-CH ₂ -morpholine) |
| MB-10 | 3021 v (CH str in phenyl ring), 1660 v (NHCO), 1303v (C-N), 1216 v (C-O) | δ7.73-7.70(2H,Ar-H),7.51-7.48(5H,Ar-H),7.34(1H,NH), 6.90-6.87(2H,Ar-H),4.41(1H,methine), 3.44-3.39(4H,O-CH ₂ -morpholine), 3.54(4H,pyrrolidin), 2.43(2H,CH ₂), 2.71-2.67(4H,N-CH ₂ -morpholine), 1.85-1.81(4H,pyrrolidin) |

Antioxidant Assay

Table 4: Percentage scavenging of DPPH radical by compounds and ascorbic acid.

| Compounds | Dilutions(μg/mL) | | | |
|---------------|------------------|---------|---------|----------|
| | 40μg/mL | 60μg/mL | 80μg/mL | 100μg/mL |
| MB-1 | 52.48% | 67.70% | 75.20% | 80.19% |
| MB-2 | 40.69% | 55.89% | 68.34% | 72.53% |
| MB-3 | 31.85% | 43.40% | 51.65% | 60.40% |
| MB-4 | 46.50% | 59.60% | 68.93% | 80.62% |
| MB-5 | 54.12% | 65.28% | 77.0% | 84.30% |
| MB-6 | 30.65% | 42.48% | 58.90% | 69.14% |
| MB-7 | 8.80% | 21.67% | 39.37% | 43.70% |
| MB-8 | 36.87% | 58.30% | 72.34% | 87.01% |
| MB-9 | 15.45% | 27.79% | 51.18% | 62.95% |
| MB-10 | 10.43% | 19.70% | 25.26% | 38.76% |
| Ascorbic acid | 65.28% | 72.14% | 86.52% | 92.38% |

The antioxidant activity of the samples were determined using the equation

$$\%E = [(A_c - A_t) / A_c] * 100,$$

Where
 E= Antioxidant activity
 A_c=Absorbance of the ABTS stock solution

Table 5: Percentage scavenging of ABTS radical by compounds and ascorbic acid.

| Compounds | Dilutions | | | |
|---------------|-----------|---------|---------|----------|
| | 40µg/mL | 60µg/mL | 80µg/mL | 100µg/mL |
| MB-1 | 38.90% | 49.20% | 64.80% | 77.50% |
| MB-2 | 25% | 39.17% | 50.60% | 58.80% |
| MB-3 | 23.40% | 35.41% | 44.50% | 56.20% |
| MB-4 | 29.70% | 45% | 62.70% | 75.50% |
| MB-5 | 39.50% | 51.20% | 68.30% | 72.70% |
| MB-6 | 18.60% | 30.66% | 45.17% | 53.02% |
| MB-7 | 10.71% | 18.30% | 30.52% | 41.64% |
| MB-8 | 30.38% | 41.50% | 61.7% | 80% |
| MB-9 | 19.57% | 30.10% | 43% | 52.80% |
| MB-10 | 13.60% | 24.14% | 31.70% | 42.60% |
| Ascorbic acid | 41.80% | 53.27% | 70.20% | 89.47% |

A= Absorbance of the test compounds

RESULTS AND DISCUSSION

In brief 10 morpholine mannich base derivatives were synthesized. The synthesized compounds were characterized by ATR and ¹H NMR spectral analysis and were found in accordance with the assigned structure. The derivatives were screened for antioxidant activity by DPPH and ABTS assay method against ascorbic acid as a standard. The results are indicated in Table 4 for DPPH Assay and Table 5 for ABTS Assay method. MB-1 and MB-8 were found to possess comparable activity to ascorbic acid using DPPH Assay method. Radical scavenging activity of compound MB-8 was significant in ABTS Assay method.

More selective compounds can be produced if further derivatization of the above molecules is carried out.

ACKNOWLEDGEMENT

Authors are thankful to Vice Chancellor and Registrar Delhi Pharmaceutical Sciences and Research University. Authors are also grateful to the staff members for providing the necessary requirements timely and for their help.

REFERENCES

- Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. *International Journal of Radiation Biology* 1994;65(1):27-33.
- Pham-Huy LA, Hua-Hue, Pham-Huy C. Free radicals, Antioxidants in Disease and Health. *International Journal of Biomedical Sciences* 2008;4(2):89-96.
- Valko M, Leibfritz D, Moncola J, Ceonin MT, Mazur M, Telser J. Review Free radicals and antioxidants in normal physiological functions and human disease. *Int J Biochemistry and Cell Biology* 2007;3(1):44-84.
- Nordberg J, Arner EJ. Reactive oxygen species, antioxidants and the mammalian Thioredoxin system. *Free Radical Biology and Medicine* 2001;31(11):1287-312.
- Gupta VK, Sharma SK. Plants as natural antioxidants. *Natural Product Radianc* 2006;5(4):326-334.
- Hekim S, Guarente L. Genetics and the specificity of the aging process. *Science* 2003;299:1351-1354.
- Vogiatzi G, Tousoulis D, Stefanadis C. The role of oxidative stress in atherosclerosis. *Hellenic Journal of Cardiology* 2009;50(5):402-409.
- Zhu DM, Shi J, Liu S, Liu Y, Zheng D. HIV infection enhances TRAIL – induced cell death in macrophage by down regulating decoy receptor expression and generation of reactive oxygen species. *PLOS One* 2011;6(4):18291.
- Koevary SB. Selective toxicity of rose Bengal to ovarian cancer cells in vitro. *Int J Physiology Pathophysiology and Pharmacology* 2012;4:99-107.
- Reddy PH. Mitochondrial dysfunction and antioxidant stress in asthma; implications for Mitochondria-targeted antioxidant therapeutics. *Pharmaceuticals(Basel)* 2011;4(3):429-456.
- Levinson SS. Humoral mechanisms in autoimmune disease. *Journal of Clinical Immunoassay* 1994;17:72-84.
- Chen AF, Chen DD, Daiber A, Faraci FM, Li H, et al. Free radical biology of the cardiovascular system. *Clinical Science* 2012;123(2):73-91.
- Hedge KR, Kovtun S, Varma SD. Induction of ultraviolet cataracts in vitro: prevention by pyruvate. *Journal of Ocular Pharmacology and Therapeutics* 2007;23:492-502.
- Oberley LW. Free radicals and diabetes. *Free Radical Biology and Medicine* 1988;5(2):113-124.
- Bashan N, Kovan J, Kachko I, Ovadia H, Rudich A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. *Physiological Reviews* 2009;89:27-71.
- Pan XD, Zhu YG, Lin N, Zhang J, Ye QY, Huang HP, Chen XC. Microglial phagocytosis induced by fibrillar β -amyloid is attenuated by oligomeric β -amyloid: implications for Alzheimer's disease. *Molecular Neurodegeneration* 2011;6(45):1-17.
- Sevesik E, Trexler AJ, Dunn JM, Rhoades E. Allosteric in a disordered protein: oxidative modifications to α -synuclein act distally to regulate membrane binding. *Journal of American Chemical Society* 2011;133(18):7152-8.
- Satyanarayana U, Chakrapani S. *Biochemistry* 3rd edition. Books and Allied (P) Ltd;2006 .p. 658,659.

19. German JB. Food processing and lipid oxidation. *Advances in Experimental Medicine and Biology* 1999;459:23-50.
20. Gutteridge JMC, Halliwell B. *Antioxidants in Nutrition, Health and Disease*. Oxford University Press, Oxford, UK;1996.
21. Shu YZ Recent natural products based drug development: a pharmaceutical industry perspective. *Journal of Natural Products* 1998;61(8): 1053-1071.
22. Vertuani S, Angusti A, Manfredini S (2004) The antioxidants and proantioxidants network: an overview. *Current Pharmaceutical Design* 10(14): 1677-1694.
23. Mensor LI, Menezes FS, Leitao GG, Reis AS, Santos DT, Coube CS, Leitao SG. Screening of Brazilian plants extracts for antioxidant activity by the use of DPPH free radical method. *Phytotherapy Research* 2001;15(2):127-130.
24. Roberta RE, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant applying an improved ABTS radical cation decolorization assay. *Free Radical Biology and Medicine* 1999;26(9-10):1231-1237.